BioLineRx (BLRX) Enterprise Value (2023 - 2025)
Historic Enterprise Value for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$25.2 million.
- BioLineRx's Enterprise Value rose 1357.76% to -$25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.2 million, marking a year-over-year increase of 1357.76%. This contributed to the annual value of -$19.6 million for FY2024, which is 5450.06% up from last year.
- According to the latest figures from Q3 2025, BioLineRx's Enterprise Value is -$25.2 million, which was up 1357.76% from -$28.2 million recorded in Q2 2025.
- BioLineRx's 5-year Enterprise Value high stood at -$19.6 million for Q4 2024, and its period low was -$43.3 million during Q1 2023.
- Its 3-year average for Enterprise Value is -$31.4 million, with a median of -$28.8 million in 2023.
- Over the last 5 years, BioLineRx's Enterprise Value had its largest YoY gain of 5450.06% in 2024, and its largest YoY loss of 2030.75% in 2024.
- BioLineRx's Enterprise Value (Quarter) stood at -$43.0 million in 2023, then soared by 54.5% to -$19.6 million in 2024, then decreased by 28.88% to -$25.2 million in 2025.
- Its Enterprise Value was -$25.2 million in Q3 2025, compared to -$28.2 million in Q2 2025 and -$26.4 million in Q1 2025.